Global requirements for dna sample collections: Results of a survey of 204 ethics committees in 40 countries

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 4, 2011, Pages 554-561

  Ricci, D S ^a   Broderick, E D ^a   Tchelet, A ^b   Hong, F ^c   Mayevsky, S ^b   Mohr, D M ^d   Schaffer, M E ^d   Warner, A W ^e   Hakkulinen, P ^f   Snapir, A ^f  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

^c AMGEN INC   (United States)

^d CENTOCOR INC   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DNA DETERMINATION; DNA SCREENING; GENETIC ANALYSIS; HUMAN; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PHARMACOGENETICS; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DNA; DRUG DESIGN; ETHICS COMMITTEES, RESEARCH; HUMANS; PHARMACOGENETICS; SPECIMEN HANDLING;

EID: 79952993467     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.319     Document Type: Article

References (20)

1. Anderson, D.C. et al.; pharmacogenetics Working Group. Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group. Pharmacogenomics J. 2, 284-292 (2002). (Pubitemid 35452485)
2. Porteri, C. & Borry, P. A proposal for a model of informed consent for the collection, Storage and use of biological materials for research purposes. Patient Educ. Couns. 71, 136-142 (2008).
3. Spear, B.B. et al.; pharmacogenetics Working Group. Terminology for sample collection in clinical genetic studies. Pharmacogenomics J. 1, 101-103 (2001)
4. International Conference on Harmonisation. Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories: E15 http://www.Ich.Org/fileadmin/public-Web- Site/iCH-products/ Guidelines/Efficacy/E15/Step4/E15-Guideline.Pdf (2007).
5. Roohi, F.H. Challenges in conducting clinical research trials in emerging market economies. Monitor 23, 31-35 (2009).
6. Koren, A. Successful start of clinical trials in israel: a roadmap for pharmaceutical and medical device trials. Monitor 21, 57-61 (2007).
7. Gupta, S.K. The current regulatory environment for clinical research in india. Monitor 23, 27-29 (2009).
8. Huang, G., Xu, Q., Zang, L., Halloran, L.A. & Zhong, J.Q. Conducting global clinical trials in asia. Monitor 23, 42-46 (2009).
9. Storozhuk, E., Khabriev, R.U. & Filunin, S.V. International clinical trials in Russia: an insider's perspective. Monitor 21, 35-39 (2007).
10. Bookman, E.B. et al.; NHLBi Working Group. Reporting genetic results in research studies: summary and recommendations of an NHLBi working group. Am. J. Med. Genet. A 140, 1033-1040 (2006).
11. Renegar, G. et al. Returning genetic research results to individuals: points-to-consider. Bioethics 20, 24-36 (2006). (Pubitemid 43168271)
12. Franc, M.A., Cohen, N., Warner, A.W., Shaw, P.M., Groenen, P. & Snapir, A. Coding of DNa samples and data in the pharmaceutical industry: current practices and future directions. Clin. Pharm. Ther. 89, 537-545 (2011).
13. Department of Health and Human Services, Centers for Disease Control and prevention. Code of Federal Regulations (10/2004) part 493 Laboratory Requirements 68 FR 64350 (2003).
14. Warner, A.W. et al. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics Working Group. Clin. Pharm. Ther. 89, 529-536 (2011).
15. Industry pharmacogenomics Working Group. Pharmacogenomics informational Brochure for iRBs/iECs and investigational Site Staff http://www.I-pwg.Org/cms/ index.Php?option=com-docman&task=cat- view&gid=106&itemid=118 (2008).
16. Industry pharmacogenomics Working Group. Understanding the intent, Scope and public Health Benefits of Exploratory Biomarker Research: a Guide for iRBs/iECs and investigational Site Staff http:// www.I-pwg.Org/cms/index.Php? option=com-docman&task=cat- view&gid=119&itemid=118 (2009)
17. Franc, M.A., Warner, A.W., Cohen, N., Shaw, P.M., Groenen, P. & Snapir, A. Current practices for DNa sample collection and storage in the pharmaceutical industry, And potential areas for harmonization. Clin. Pharm. Ther. 89, 546-553 (2011).
18. US Food and Drug administration. Meeting of advisory Committee for pharmaceutical Science and Clinical pharmacology. http://www.Fda.Gov/downloads/ advisoryCommittees/CommitteesMeetingMaterials/Drugs/ advisoryCommitteeforpharmaceuticalScienceandClinicalpharmacology/ UCM210803.Pdf (2010).
19. R Development Core Team. R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria http://www.R-project.Org/ (2010).
20. Brazil Ministry of Health. Rules on Research involving Human Subjects (Res. CNS 196/96 and others) http://conselho.Saude.Gov.Br/biblioteca/livros/ Normas-pesquisa.Pdf (2000).